Investigation of an NQO1 polymorphism as a possible risk and prognostic factor for chronic lymphocytic leukemia

Leukemia Research

Volumn 33, Issue 1, 2009, Pages 74-81

  Begleiter, Asher ^a,b   Hewitt, Donna ^a   Gibson, Spencer B ^a,b   Johnston, James B ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Chronic lymphocytic leukemia; NQO1; Polymorphism; Prognostic factor; Risk factor

Indexed keywords

CHLORAMBUCIL; CISPLATIN; DOXORUBICIN; FLUDARABINE; OXIDOREDUCTASE; PACLITAXEL; PROTEIN P53; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE QUINONE OXIDOREDUCTASE 1; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DNA POLYMORPHISM; ENZYME ACTIVITY; FEMALE; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NAD(P)H DEHYDROGENASE (QUINONE); POLYMORPHISM, GENETIC; PROGNOSIS; RISK FACTORS;

EID: 55249125910     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.06.030     Document Type: Article

References (48)

1. Johnston J.B. Chronic lymphocytic leukemia. In: Greer J.P., Foerster J., Lukens J., Paraskevas F., Rodgers G.M., and Glader B.E. (Eds). Wintrobe's clinical hematology. 11th ed. (2003), Williams and Wilkins, Baltimore
2. Schena M., Larsson L.G., Gottardi D., Gaidano G., Carlsson M., Nilsson K., et al. Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood 79 (1992) 2981-2989
3. Menzel T., Rahman Z., Calleja E., White K., Wilson E.L., Wieder R., et al. Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine. Blood 87 (1996) 1056-1063
4. Delmer A., Ajchenbaum-Cymbalista F., Tang R., Ramond S., Faussat A.M., Marie J.P., et al. Overexpression of cyclin D2 in chronic B-cell malignancies. Blood 85 (1995) 2870-2876
5. Zhao H., Dugas N., Mathiot C., Delmer A., Dugas B., Sigaux F., et al. B-cell chronic lymphocytic leukemia cells express a functional inducible nitric oxide synthase displaying anti-apoptotic activity. Blood 92 (1998) 1031-L1043
6. Vrhovac R., Delmer A., Tang R., Marie J.P., Zittoun R., and Ajchenbaum-Cymbalista F. Prognostic significance of the cell cycle inhibitor p27Kipl in chronic lymphocytic leukemia cells. Blood 91 (1998) 4694-4700
7. Döhner H., Stilgenbauer S., Benner A., Leupolt E., Krober A., Bullinger L., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343 (2000) 1910-1916
8. Oscier D.G., Gardiner A.C., Mould S.J., Glide S., Davis Z.A., Ibbotson R.E., et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 100 (2002) 1177-1184
9. Rassenti L.Z., Huynh L., Tay T.L., Chen L., Keating M.J., Gribben J.G., et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 351 (2004) 893-901
10. Rai K.R., Peterson B.L., Appelbaum F.R., Kolitz J., Elias L., Shepherd L., et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343 (2000) 1750-1757
11. Keating M.J., Flinn I., Jain V., Binet J.L., Hillmen P., Byrd J., et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99 (2002) 3554-3561
12. Byrd J.C., Rai K., Peterson B.L., Appelbaum F.R., Morrison V.A., Kolitz J.E., et al. The addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105 (2005) 49-53
13. Elter T., Bochmann P., Schulz H., Reiser M., Trelle S., Schnell R., et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 23 (2005) 7024-7031
14. Ritgen M., Stilgenbauer S., von Neuhoff N., Humpe A., Bruggemann M., Pott C., et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood 104 (2004) 2600-2602
15. Ross D., Siegel D., Beall H., Prakash A.S., Mulcahy R.T., and Gibson N.W. DT-diaphorase in activation and detoxification of quinones. Cancer Metast Rev 12 (1993) 83-101
16. Riley R.J., and Workman P. DT-diaphorase and cancer chemotherapy. Biochem Pharmacol 43 (1992) 1657-1669
17. Ernster L. DT-diaphorase: a historical review. Chem Scripta 27A (1987) 1-13
18. Begleiter A., Robotham E., Lacey G., and Leith M.K. Increased sensitivity of quinone resistant cells to mitomycin C. Cancer Lett 45 (1989) 173-176
19. Begleiter A., Leith M.K., Curphey T.J., and Doherty G.P. Induction of DT-diaphorase in cancer chemoprevention and chemotherapy. Oncol Res 9 (1997) 371-382
20. Jaiswal A.K. Human NAD(P)H:quinone oxidoreductase (NQO-l) gene structure and induction by dioxin. Biochemistry 30 (1991) 10647-10653
21. Belinsky M., and Jaiswal A.K. NAD(P)H:quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues. Cancer Metastasis Rev 12 (1993) 103-117
22. Schlager J.J., and Powis G. Cytosolic NAD(P)H:(quinone-acceptor)oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. Int J Cancer 45 (1990) 403-409
23. Traver R.D., Siegel D., Beall H.D., Phillips R.M., Gibson N.W., Franklin W.A., et al. Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br J Cancer 75 (1997) 69-75
24. Kelsey K.T., Ross D., Traver R.D., Christiani D.C., Zuo Z.F., Spitz M.R., et al. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br J Cancer 76 (1997) 852-854
25. Gaedigk A., Tyndale R.F., Jurima-Romet M., Sellers E.M., Grant D.M., and Leeder J.S. NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations. Pharmacogenetics 8 (1998) 305-313
26. Wiencke J.K., Spitz M.R., McMillan A., and Kelsey K.T. Lung cancer in Mexican-Americans and African-Americans is associated with the wild-type genotype of the NAD(P)H:quinone oxidoreductase polymorphism. Cancer Epidemiol Biomarkers Prev 6 (1997) 87-92
27. Misra V., Klamut H.J., and Rauth A.M. Transfection of COS-1 cells with DT-diaphorase cDNA: role of a base change at position 609. Br J Cancer 77 (1998) 1236-1240
28. Begleiter A., Leith M.K., Dohert G.P., Digby T.J., and Pan S. Factors influencing the induction of DT-diaphorase activity by 1, 2-dithiole-3-thione in human tumour cell lines. Biochem Pharmacol 61 (2001) 955-964
29. Smith T., Musk S.R.R., and Johnson I.T. Allyl isothiocyanate selectively kills undifferentiated HT29 cells in vitro and suppresses aberrant crypt foci in the colonic mucosa of rats. Biochem Soc Trans 24 (1996) 381S
30. Park S.-J., Zhao H., Spitz M.R., Grossman H.B., and Wu X. An association between NQO1 genetic polymorphism and risk of bladder cancer. Mutat Res 536 (2003) 131-137
31. Menze H.-J., Sarmanova J., Soucek P., Berberich R., Grunewald K., Haun M., et al. Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations. Br J Cancer 90 (2004) 1989-1994
32. Zhang J.-H., Li Y., Wang R., Geddert H., Guo W., Wen D.G., et al. NQO1 C609T polymorphism associated with esophageal cancer and gastric cardiac carcinoma in North China. World J Gastroenterol 9 (2003) 1390-1393
33. Schulz W.A., Krummeck A., Rosinger I., Eickelmann P., Neuhaus C., Ebert T., et al. Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics 7 (1997) 235-239
34. Lafuente M.J., Casterad X., Trias M., Ascaso C., Molina R., Ballesta A., et al. NAD(P)H:quinone oxidoreductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors. Carcinogenesis 21 (2000) 1813-1819
35. Wiemels J.L., Pagnamenta A., Taylor G.M., Edens O.B., Alexander F.E., and Greaves M.F. A lack of a functional NAD(P)H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. Cancer Res 59 (1999) 4095-4099
36. Krajinovic M., Sinnett H., Richer C., Labuda D., and Sinnett D. Role of NQO1, MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Int J Cancer 97 (2002) 230-236
37. Larson R.A., Wang Y., Banerjee M., Wiemels J., Hartford C., Le Beau M.M., et al. Prevalence of the inactivating 609C→T polymorphism in the NAD(P)H:quinoneoxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood 94 (1999) 803-807
38. Smith M.T., Wang Y., Kane E., Rollinson S., Wiemels J.L., Roman E., et al. Low NAD(P)H:quinone oxidoreductase 1 activity is associated with increased risk of acute leukemia in adults. Blood 97 (2001) 1422-1426
39. El Rouby S., Thomas A., Costin D., Rosenberg C.R., Potmesil M., Silber R., et al. p53 Gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82 (1993) 3452-3459
40. Johnston J.B., Daeninck P., Verburg L., Lee K., Williams G., Israels L.G., et al. P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia. Leuk Lymph 26 (1997) 435-449
41. Asher G., Lotem J., Cohen B., Sachs L., and Shaul Y. Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc Natl Acad Sci 98 (2001) 1188-1193
42. Long II D.J., Gaikwad A., Multani A., Pathak S., Montgomery C.A., Gonzalez F.J., et al. Disruption of the NAD(P)H:quinone oxidoreductase 1 (NQO1) gene in mice causes myelogenous hyperplasia. Cancer Res 62 (2002) 3030-3036
43. Begleiter A., Norman A., Leiteo D., Cabral T., Hewitt D., Pan S., et al. Role of NQO1 polymorphisms as risk factors for squamous cell carcinoma of the head and neck. Oral Oncol 41 (2005) 927-933
44. Johnston J.B., Verburg L., Shore T., Williams M., Israels L.G., and Begleiter A. Combination therapy with nucleoside analogs and alkylating agents. Leukemia 8 Suppl. 1 (1994) S140-S143
45. Kabore A.F., Sun J., Hu X., McCrea K., Johnston J.B., and Gibson S.B. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells. Apoptosis 11 (2006) 1175-1193
46. Hamajima N., Matsuo K., Iwata H., Shinoda M., Yamamura Y., Kato T., et al. NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese. Int J Clin Oncol 7 (2002) 103-108
47. Walewska R., Majid A., Davis Z., Dusanjh P., Kennedy D.B., Oscier D.G., et al. Male preponderance in chronic lymphocytic leukemia utilizing IGHV 1-69. Leukemia 21 (2007) 2537-2538
48. Begleiter A., and Israels L.G. Antineoplastic agents. In: Israels L.G., and Israels E.D. (Eds). Mechanisms in hematology. 3rd ed. (2002), Core Health Services Inc., Concord, ON 289-308